关键信息
-
基因名
Coagulation Factor X/F10
- 应用
-
别名
FX; FXA; Stuart Prower Factor; Thrombokinase
-
种属
Mouse
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
O88947
-
表达区间
Gly21~Asn481
-
分子量
56kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
Coagulation Factor X, also known as F10, is a crucial component of the coagulation cascade, playing a vital role in hemostasis by converting prothrombin to thrombin, which subsequently leads to fibrin formation and blood clotting. Deficiencies in Factor X can result in bleeding disorders, highlighting the need for therapeutic interventions. Recombinant Factor X proteins have emerged as significant biopharmaceuticals, offering advantages over plasma-derived proteins, such as greater safety, reduced risk of viral transmission, and enhanced stability. The development of recombinant Factor X has been driven by advancements in biotechnology, including genetic engineering techniques and the use of mammalian cell systems for protein production. Research into recombinant F10 has focused on optimizing its functional properties, improving its pharmacokinetics, and enhancing its efficacy in treating coagulopathies. Moreover, novel formulations and delivery methods are being explored to maximize patient outcomes, particularly in the context of hemophilia and congenital Factor X deficiency. As the understanding of Factor X's role in the coagulation pathway deepens, ongoing studies aim to fine-tune its therapeutic applications, paving the way for more effective and personalized treatment strategies for patients affected by bleeding disorders.
